The proposed molecular platform for PSMA delivery consists of two parts: (1) a vector fragment providing conjugate-directed delivery to the prostate cancer cells and (2) a polypeptide linker providing a possibility of subsequent conjugation with therapeutic and diagnostic (or two therapeutic) agents and increasing affinity to the PSMA receptor. The gene discussed is FOLH1; the disease is prostate carcinoma.